We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Taula Rodona Venture Summit Vall d'Hebron 2024
Presentació Venture Summit VH
Taula Rodona Venture Summit VH
El VHIR organitza la primera trobada entre emprenedors i l’ecosistema inversor.
The first Vall d'Hebron Ventures Summit took place on May 6th. It is a meeting organised by VHIR to bring together its spin-offs and their corresponding investors, with the aim of building a community among them. Although many already know each other because they have met at other events, VHIR aims to be the link that reinforces the ties and provides visibility to all the stakeholders.
On this event, fifteen of our spin-offs were briefly presented: Imidomics (Sara Marsal, CMO), Bsure Medical (Menno Marien), Mimark Diagnostics (Marina Rigau), Endolipid Therapeutics & Endolipid Derma (David Martínez-Selva, CSO), Tensor Medical (Sergi Valverde), Frontwave (Cristina Duran), Nora Health (Ariadna Oroval), Abcdx (Jean-Charles Sanchez), Manina Medtech (Mónica Rodríguez, vídeo), D-Sight (Carla Maté), heecap (Laura Lizama), Ysotope theranostics (Carlos Langeberg), Artis Development (Raul Guerra), Trackyourmed (Oriol Bestard). Thus, the attendees were able to get an overview of what the entrepreneurs are working on and the current stage they are at.
The round panel ‘The 3 perspectives of an investment round’ exposed the three visions of this stage which often generates conflict between investors and entrepreneurs. Participants included Marina Rigau, CEO and co-founder of MiMARK, Laura Rodríguez, investor at Invivo Partners, and Antoni Rosselló, lawyer at RCD. In fact, lawyers also play a very significant role mediating and supporting during all the stages of the investment rounds.
In addition, other investors were invited in order they could learn about new opportunities in this community. The event was also opened to all the Campus Vall d'Hebron researchers in order to encourage entrepreneurialism.
This meeting was created to become an annual event of reference in the sector to facilitate the recruitment of both national as well as international investors of and for our companies. According to Rafael Navajo, Director of Innovation and Business Development at the VHIR, "it is a unique opportunity to create a network of connections between different environments, which will help us maintain our position as a reference centre in innovation management. It also allows us to continue positively impacting patient society'.
Una trobada per reunir a les seves spin-off i els seus corresponents inversors amb l’objectiu de crear una comunitat entre ells.
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.